Autologous Stem Cell Transplantation: International Lupus Trial
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate remission induction therapy for refractory Lupus
Erythematosus with autologous hematopoietic stem cell transplantation (AHSCT) versus
Rituximab (anti CD20) followed by maintenance therapy with mycophenolate mofetil (MMF).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
European Society for Blood and Marrow Transplantation